Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Usha Lee McFarling ...

Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 ...